Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted ...

This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and Eisai, was first rejected for NHS coverage in August 2024, while a negative ...

The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...

NEW YORK – The UK National Institute for Health and Care Excellence on Thursday issued two updated draft guidances recommending against making Eisai and Biogen's Leqembi (lecanemab) and Eli Lilly's ...

Good morning everyone, it’s Jason Mast, filling in for Ed. Today I’m in Pharmalittle’s New York bureau, sipping a cup poured from a French press gifted to me by my sisters, made from beans ...

Antibodies are secreted immunoglobulin molecules produced mainly by plasma cells. The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the treatment of patients with Mild Cognitive Impairment (MCI) ...

TOKYO and CAMBRIDGE, Mass., Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Biogen/Eisai’s LEQEMBI (lecanemab) Overview LEQEMBI, developed by Biogen and Eisai, is a humanized IgG1 monoclonal antibody targeting both soluble aggregated forms (protofibrils) and insoluble ...